Cardiovascular Revascularization Medicine最新文献

筛选
英文 中文
Balloon-assisted vascular closure after TAVI: Beyond reported vascular complications. TAVI后球囊辅助血管闭合:超越报道的血管并发症。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-12 DOI: 10.1016/j.carrev.2026.11.007
Teruhiko Imamura
{"title":"Balloon-assisted vascular closure after TAVI: Beyond reported vascular complications.","authors":"Teruhiko Imamura","doi":"10.1016/j.carrev.2026.11.007","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.11.007","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical impact of blood loss during mechanical thrombus aspiration for pulmonary embolism intervention, a sub-analysis of the USAT IH-PE registry. 机械血栓吸入对肺栓塞干预的临床影响,USAT IH-PE登记的亚分析。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-09 DOI: 10.1016/j.carrev.2026.11.002
Mario Iannaccone, Luca Franchin, Claudia Colombo, Nicolò Capsoni, Marco Balducci, Riccardo Mazza, Davide Raspanti, Matteo Michelone, Maurizio Bertaina, Elena Gualini, Federica Fumarola, Daniele Savio, Filippo Russo, Giacomo Boccuzzi, Fabrizio Oliva, Alice Sacco
{"title":"Clinical impact of blood loss during mechanical thrombus aspiration for pulmonary embolism intervention, a sub-analysis of the USAT IH-PE registry.","authors":"Mario Iannaccone, Luca Franchin, Claudia Colombo, Nicolò Capsoni, Marco Balducci, Riccardo Mazza, Davide Raspanti, Matteo Michelone, Maurizio Bertaina, Elena Gualini, Federica Fumarola, Daniele Savio, Filippo Russo, Giacomo Boccuzzi, Fabrizio Oliva, Alice Sacco","doi":"10.1016/j.carrev.2026.11.002","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.11.002","url":null,"abstract":"<p><strong>Introduction: </strong>The clinical impact and critical threshold of intraprocedural blood loss (BL) during large-bore aspiration thrombectomy for pulmonary embolism (PE) remain poorly defined. This study evaluates how blood loss influences major bleeding events and in-hospital mortality.</p><p><strong>Methods: </strong>We analysed 104 patients undergoing aspiration thrombectomy for PE in the USAT IH-PE registry with recorded intraprocedural blood loss (mL). Outcomes were major bleeding (BARC ≥3), death and a composite endpoint. Exploratory analyses were repeated, stratified by pre-procedural Hb (<11 vs ≥11 g/dL).</p><p><strong>Results: </strong>Median blood loss was 300 mL; bleeding occurred in 21%, death in 7% and the composite endpoint in 22%. Blood loss correlated only weakly with the Hb drop and not after adjustment. It was higher in patients with major bleeding (380 ± 121 mL vs 289 ± 122 mL, AUC 0.72; OR 1.74 per +100 mL) and the composite endpoint (358 ± 116 mL vs 293 ± 127 mL, AUC 0.67), but unrelated to mortality. In an exploratory subgroup analysis, the association with major bleeding appeared stronger in patients with Hb <11 g/dL (n = 22; AUC 0.93). Independent predictors of the composite endpoint were blood loss (aOR 2.18, 1.35-3.52, p = 0.001), lower pre-procedural Hb (aOR 0.65, 0.48-0.89, p = 0.006) and high-risk PE (aOR 12.01, 3.42-42.25, p < 0.001). In the full cohort, a ≥ 280 mL threshold predicted major bleeding with 91% sensitivity and 95% negative predictive value. Results were consistent after adjustment for device type.</p><p><strong>Conclusions: </strong>Intraprocedural blood loss independently predicts bleeding and adverse outcomes after aspiration thrombectomy for PE, possibly more so in anaemic patients, and a ≥ 280 mL threshold may support risk stratification.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug-eluting stent-based versus drug-coated balloon-based strategies for left main coronary bifurcation disease: A systematic review and meta-analysis. 药物洗脱支架vs药物包被球囊治疗左主干冠状动脉分叉疾病:系统回顾和荟萃分析
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-07 DOI: 10.1016/j.carrev.2026.11.001
Ricardo F O Suruagy-Motta, Laila Leite Pacheco Vieira, Marcela Caracas Machado Borges, Ana Beatriz P Aguiar-Barros, Marina Amaral Barros da Cruz Oliveira Menezes, Gabriel Lima Vieira Barbosa, Lucas Ferreira Paz Silva, Sidney Ramos Borges Filho, Clarissa Dall'Orto, Gilvan Viella Pinto Filho, Sant Kumar, Lorenzo Azzalini, C Michael Gibson, Pedro E P Carvalho, Evandro Martins Filho, Emmanouil S Brilakis
{"title":"Drug-eluting stent-based versus drug-coated balloon-based strategies for left main coronary bifurcation disease: A systematic review and meta-analysis.","authors":"Ricardo F O Suruagy-Motta, Laila Leite Pacheco Vieira, Marcela Caracas Machado Borges, Ana Beatriz P Aguiar-Barros, Marina Amaral Barros da Cruz Oliveira Menezes, Gabriel Lima Vieira Barbosa, Lucas Ferreira Paz Silva, Sidney Ramos Borges Filho, Clarissa Dall'Orto, Gilvan Viella Pinto Filho, Sant Kumar, Lorenzo Azzalini, C Michael Gibson, Pedro E P Carvalho, Evandro Martins Filho, Emmanouil S Brilakis","doi":"10.1016/j.carrev.2026.11.001","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.11.001","url":null,"abstract":"<p><strong>Background: </strong>Left main coronary bifurcation disease remains challenging to treat percutaneously, and permanent stent implantation carries limitations related to chronic vascular inflammation and prolonged dual antiplatelet therapy. Drug-coated balloon (DCB) angioplasty has emerged as an implant-sparing alternative to drug-eluting stents (DES), but comparative evidence in left main disease is limited. We performed a systematic review and meta-analysis comparing DCB- and DES-based strategies in left main bifurcation lesions.</p><p><strong>Methods: </strong>This study followed PRISMA 2020 guidelines and was prospectively registered on PROSPERO (CRD420261451299). PubMed/MEDLINE, Embase, Cochrane CENTRAL, Scopus, and Web of Science were searched through October 2026. The primary outcome was target lesion revascularization (TLR); secondary outcomes included major adverse cardiac events (MACE), all-cause mortality, cardiac death, and myocardial infarction. Random-effects models (DerSimonian-Laird) were used to pool risk ratios (RRs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>Nine retrospective cohort studies (2018-2026) met the inclusion criteria; no randomized trial directly comparing DCB- and DES-based strategies in left main disease was identified. Across the nine studies (1336 patients; 40.5% DCB), TLR did not differ significantly between strategies (DES vs DCB: RR 1.17; 95% CI 0.75-1.82; I<sup>2</sup> = 32.3%; Bayesian RR 1.16; 95% CrI 0.73-1.84). No significant differences were observed for MACE (RR 1.07; 95% CI 0.74-1.54), all-cause mortality (RR 1.22; 95% CI 0.61-2.45), cardiac death (RR 1.71; 95% CI 0.91-3.23), or myocardial infarction (RR 1.33; 95% CI 0.78-2.25), with consistent Bayesian estimates.</p><p><strong>Conclusions: </strong>DES-based and DCB-based strategies for left main bifurcation lesions were not associated with significant differences in efficacy or safety outcomes. DCB-based treatment appeared feasible in the selected patients studied, although current evidence does not establish equivalence, and dedicated randomized trials are needed.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additional value of optical coherence tomography-fractional flow reserve for the optimization of percutaneous coronary intervention. 光学相干层析-分数血流储备在优化经皮冠状动脉介入治疗中的附加价值。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-05 DOI: 10.1016/j.carrev.2026.10.022
Jacopo Farina, Sant Kumar, Gianluca Campo, Andrea Marrone, Ahmad Jabri, Iginio Colaiori, Jennifer Meinen, JoAnna McNutt, Gopinath Ajay, Wei Che Chiu, Andrea Erriquez, Simone Biscaglia
{"title":"Additional value of optical coherence tomography-fractional flow reserve for the optimization of percutaneous coronary intervention.","authors":"Jacopo Farina, Sant Kumar, Gianluca Campo, Andrea Marrone, Ahmad Jabri, Iginio Colaiori, Jennifer Meinen, JoAnna McNutt, Gopinath Ajay, Wei Che Chiu, Andrea Erriquez, Simone Biscaglia","doi":"10.1016/j.carrev.2026.10.022","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.022","url":null,"abstract":"<p><strong>Background: </strong>Post-percutaneous coronary intervention (PCI) optimization remains largely driven by intravascular imaging, potentially leading to overtreatment of functionally irrelevant findings.</p><p><strong>Objectives: </strong>To compare the impact of optical coherence tomography (OCT), angiography-derived fractional flow reserve (FFR<sub>angio</sub>), and the integration of imaging and physiology (OCT-FFR) on post-PCI optimization strategies.</p><p><strong>Methods: </strong>Among patients included in the AQVA-I and II trials, we selected those receiving post-PCI OCT (n = 79). Physiology reconstruction based on OCT traces was obtained in 76 OCT runs. One operator, blinded to the post-PCI optimization procedural plan and to final PCI result, planned the procedure according to FFR<sub>angio</sub>, OCT and OCT-FFR. The primary endpoint was the rate of any additional post-PCI optimization maneuver. Secondary endpoints included type of optimization strategy and pairwise differences between modalities.</p><p><strong>Results: </strong>Among 79 patients, 76 had complete triplet data. The rate of any additional post-PCI optimization was highest with OCT (33/76, 43.4%), followed by OCT-FFR (26/76, 34.2%) and lowest with FFR<sub>angio</sub> (5/76, 6.6%) (overall p < 0.001). The overall rate of any additional maneuver was not significantly different between OCT and OCT-FFR (absolute paired difference 2.6%; adjusted p = 0.500). Recommendations for edge dissection stenting, post-dilation for stent underexpansion, and post-dilation for malapposition were identical between OCT and OCT-FFR. In contrast, additional stenting of adjacent segments was reduced with OCT-FFR compared with OCT (4/76 [5.3%] vs 12/76 [15.8%]) and was recommended at the same rate as with FFRangio (4/76 [5.3%]).</p><p><strong>Conclusions: </strong>OCT guidance is associated with a higher rate of post-PCI optimization maneuvers compared with FFR<sub>angio</sub>, reflecting its sensitivity to morphological abnormalities. Integration of functional assessment through OCT-FFR significantly reduces additional stenting in segments defined as 5 mm proximal and distal to the stent edges, while preserving treatment of clinically relevant mechanical complications.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Occlusion myocardial infarction without ST-elevation is associated with delayed angiography and a higher risk of cardiovascular events. 无st段抬高的闭塞性心肌梗死与延迟血管造影和更高的心血管事件风险相关。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-02 DOI: 10.1016/j.carrev.2026.10.019
André Lobo, Gonçalo Leal, Francisco Sousa, Francisca Nunes, Marta Catarina Almeida, Francisco Sampaio, Ricardo Fontes-Carvalho
{"title":"Occlusion myocardial infarction without ST-elevation is associated with delayed angiography and a higher risk of cardiovascular events.","authors":"André Lobo, Gonçalo Leal, Francisco Sousa, Francisca Nunes, Marta Catarina Almeida, Francisco Sampaio, Ricardo Fontes-Carvalho","doi":"10.1016/j.carrev.2026.10.019","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.019","url":null,"abstract":"<p><strong>Background: </strong>ST-segment elevation decides who undergoes immediate angiography, yet a quarter to a third of patients without it have an occlusion myocardial infarction (OMI) and follow the slower non-ST-elevation pathway. Their outcome over extended follow-up compared with ST-elevation myocardial infarction (STEMI), including non-fatal events, is poorly defined.</p><p><strong>Methods: </strong>In a retrospective single-centre cohort, we reclassified 313 consecutive patients with acute coronary syndrome undergoing angiography as STEMI, NSTEMI-OMI, or NSTEMI-non-OMI. OMI was pre-specified as culprit TIMI flow ≤2, and/or markedly elevated peak troponin with a new wall-motion abnormality. The composite of death, recurrent myocardial infarction, or cardiovascular readmission was assessed at 12 months and over a median follow-up of 26.2 months.</p><p><strong>Results: </strong>Of 313 patients, 177 had STEMI and 136 had no ST-elevation, of whom 54 (39.7%) fulfilled OMI criteria. Median time to angiography was 10.1 h in NSTEMI-OMI versus 1.0 h in STEMI (p < 0.001) and 15.9 h in NSTEMI-non-OMI (p = 0.140). The 12-month composite occurred in 16.7% of NSTEMI-OMI, 3.4% of STEMI, and 2.4% of NSTEMI-non-OMI (p = 0.001). The adjusted hazard ratio for NSTEMI-OMI was 3.46 (95% CI 1.70-7.02) versus STEMI and 3.31 (1.43-7.63) versus NSTEMI-non-OMI. In patients event-free at 12 months, the unadjusted hazard ratio versus STEMI was 3.56 (1.40-9.05).</p><p><strong>Conclusions: </strong>Patients with OMI but no ST-segment elevation waited longer for angiography than STEMI and had a higher hazard of the composite outcome than both other groups, an excess persisting beyond the first year.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149344080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Robotic-assisted versus manual percutaneous coronary intervention after contemporary randomized evidence: An updated systematic review and meta-analysis of patient-level procedural and radiation outcomes. 当代随机证据表明,机器人辅助与人工经皮冠状动脉介入治疗:一项更新的系统综述和患者水平手术和放疗结果的荟萃分析。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-02 DOI: 10.1016/j.carrev.2026.10.020
Kumail Razvi, Maroun Ibrahim, Umer Irshad, Ramza Ishac, Zunaira Shah, Ahmad Al Taweel, Bahaeddine Shabaneh, Molham Aldeiri
{"title":"Robotic-assisted versus manual percutaneous coronary intervention after contemporary randomized evidence: An updated systematic review and meta-analysis of patient-level procedural and radiation outcomes.","authors":"Kumail Razvi, Maroun Ibrahim, Umer Irshad, Ramza Ishac, Zunaira Shah, Ahmad Al Taweel, Bahaeddine Shabaneh, Molham Aldeiri","doi":"10.1016/j.carrev.2026.10.020","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.020","url":null,"abstract":"<p><strong>Background: </strong>Robotic-assisted PCI (R-PCI) reduces measured radiation exposure to the primary operator, but procedural and patient-radiation benefits over manual PCI (M-PCI) remain uncertain.</p><p><strong>Objectives: </strong>To compare procedural/PCI time, fluoroscopy time, contrast volume, air kerma, and dose-area product between R-PCI and M-PCI after incorporation of randomized evidence.</p><p><strong>Methods: </strong>Randomized and nonrandomized comparative studies of adults undergoing PCI were included. Random-effects models used restricted maximum likelihood with modified Hartung-Knapp inference. Mean differences (MDs) were calculated as M-PCI minus R-PCI. Risk of bias was assessed using RoB 2 and ROBINS-I; certainty was assessed using GRADE.</p><p><strong>Results: </strong>Twelve studies, including 2 randomized trials, contributed data. No primary pooled outcome differed significantly: procedural/PCI time, MD -3.90 min (95% CI: -16.15 to 8.35); fluoroscopy time, 0.17 min (95% CI: -2.61 to 2.95); contrast volume, 7.79 mL (95% CI: -3.08 to 18.66); air kerma, 232.01 mGy (95% CI: -145.67 to 609.70); and dose-area product, 31.31 dGy·cm<sup>2</sup> (95% CI: -49.45 to 112.07). Heterogeneity was substantial (I<sup>2</sup> = 72%-93%). A direct-report-only analysis favored R-PCI for contrast volume (MD: 17.76 mL; 95% CI: 4.62-30.90), but other sensitivity analyses did not materially change interpretation. Certainty was very low for all outcomes.</p><p><strong>Conclusions: </strong>R-PCI has not shown consistent patient procedural or radiation benefit. Operator protection is supported descriptively but was not pooled; contrast reduction appeared only in sensitivity analysis. Future trials should assess patient benefit and team-wide occupational exposure.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of patient sex and dual antiplatelet therapy duration on 10-year mortality following percutaneous coronary intervention with drug-eluting stents: A post-hoc analysis of the ISAR-SAFE trial. 患者性别和双重抗血小板治疗持续时间对经皮冠状动脉药物洗脱支架介入术后10年死亡率的影响:ISAR-SAFE试验的事后分析
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-11-02 DOI: 10.1016/j.carrev.2026.10.021
Maddalena Immobile Molaro, Katharina Mayer, Fiorenzo Simonetti, Doruntina Lahu, Martina Edda Lickel, Yi Li, Barbara von Merzljak, Esther Brennicke, Karl-Ludwig Laugwitz, Melchior Seyfarth, Salvatore Cassese, Kambis Mashayekhi, Isabell Bernlochner, Adnan Kastrati, Yaling Han, Erion Xhepa
{"title":"Impact of patient sex and dual antiplatelet therapy duration on 10-year mortality following percutaneous coronary intervention with drug-eluting stents: A post-hoc analysis of the ISAR-SAFE trial.","authors":"Maddalena Immobile Molaro, Katharina Mayer, Fiorenzo Simonetti, Doruntina Lahu, Martina Edda Lickel, Yi Li, Barbara von Merzljak, Esther Brennicke, Karl-Ludwig Laugwitz, Melchior Seyfarth, Salvatore Cassese, Kambis Mashayekhi, Isabell Bernlochner, Adnan Kastrati, Yaling Han, Erion Xhepa","doi":"10.1016/j.carrev.2026.10.021","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.021","url":null,"abstract":"<p><strong>Background: </strong>Women are underrepresented in cardiovascular clinical trials and evidence regarding sex-specific long-term outcomes after percutaneous coronary intervention (PCI) remains limited.</p><p><strong>Objectives: </strong>To investigate the association between patient sex and duration of dual antiplatelet therapy (DAPT) with the 10-year prognosis of patients enrolled in the randomized, double-blind, placebo-controlled ISAR-SAFE trial.</p><p><strong>Methods: </strong>This post-hoc analysis included 1,871 patients from centers that participated in the ISAR-SAFE trial and agreed to collect 10-year follow-up data. In the ISAR-SAFE trial, a 6-month DAPT duration was compared with a 12-month DAPT regimen in patients treated with drug-eluting stents (DES). The primary endpoint of the present study was all-cause death at 10 years.</p><p><strong>Results: </strong>Compared to men, women were older (69.0 ± 9.7 vs. 64.8 ± 10.4 years, P < 0.001), had lower body weight (72.1 ± 14.2 vs. 84.8 ± 13.5 Kg, P < 0.001) and a higher prevalence of arterial hypertension (93.2% vs. 89.3%, P = 0.031) and dyslipidemia (85.1% vs. 77.9%, P = 0.003). The 10-year mortality was 11.9% in women and 9.3% in men (hazard ratio [HR] 1.28 [95% confidence interval 0.91-1.81], P = 0.156). The 10-year mortality was 10.1% in the 6-month DAPT arm and 9.6% in the 12-month DAPT arm (HR 1.06 [0.79-1.42], P = 0.685). There was no significant interaction between sex and DAPT duration with respect to mortality. Age was the only independent predictor of mortality (adjusted HR per 1 year increase 1.08 [1.06-1.09]; P < 0.001).</p><p><strong>Conclusions: </strong>Among patients undergoing PCI with DES implantation, neither patient sex nor duration of DAPT regimen were independently associated with 10-year all-cause mortality after adjustment for relevant clinical covariates.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beta-blocker continuation versus interruption during transcatheter aortic valve implantation: Rationale and design of the BETA-TAVI randomized trial. 经导管主动脉瓣置入术中β受体阻滞剂继续使用与中断:β - tavi随机试验的基本原理和设计。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-10-31 DOI: 10.1016/j.carrev.2026.10.015
Leonidas Koliastasis, Odysseas Katsaros, Charis Armonis, Nikolaos Ktenopoulos, Spyridon Karpathiotakis, Ioannis Doundoulakis, Iro Ntaga, Dimitrios Tsiachris, Sotirios Tsalamandris, Andreas Synetos, Christos Eftychiou, Vlasios Ninios, Athanasios Trikas, Konstantinos Tsioufis, Konstantinos Toutouzas
{"title":"Beta-blocker continuation versus interruption during transcatheter aortic valve implantation: Rationale and design of the BETA-TAVI randomized trial.","authors":"Leonidas Koliastasis, Odysseas Katsaros, Charis Armonis, Nikolaos Ktenopoulos, Spyridon Karpathiotakis, Ioannis Doundoulakis, Iro Ntaga, Dimitrios Tsiachris, Sotirios Tsalamandris, Andreas Synetos, Christos Eftychiou, Vlasios Ninios, Athanasios Trikas, Konstantinos Tsioufis, Konstantinos Toutouzas","doi":"10.1016/j.carrev.2026.10.015","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.015","url":null,"abstract":"<p><strong>Background: </strong>Beta-blockers are common in patients referred for transcatheter aortic valve implantation (TAVI), but there is no consensus on whether they should be continued through the procedure. Continuation could worsen bradycardia or atrioventricular block in a setting already prone to conduction injury, whereas interruption may provoke adrenergic rebound, tachyarrhythmia, myocardial ischemia, or hemodynamic instability. Available evidence is observational and does not resolve this trade-off.</p><p><strong>Methods: </strong>BETA-TAVI is an investigator-initiated, multicenter, open-label, randomized noninferiority trial in adults with severe symptomatic aortic stenosis undergoing TAVI while receiving chronic oral beta-blocker therapy. Participants are randomized 1:1 to continuation of their usual beta-blocker or interruption from 72 h before TAVI through day 7. The primary endpoint is new permanent pacemaker implantation (PPI) within 7 days. Secondary endpoints include high-degree atrioventricular block, new conduction disturbances, atrial and ventricular arrhythmias, severe bradycardia, hemodynamic deterioration, mortality, and later PPI. The calculated sample size is 348 participants. The prespecified noninferiority margin is 6.5 percentage points on the absolute risk-difference scale; the primary conclusion requires concordant modified intention-to-treat and per-protocol analyses.</p><p><strong>Conclusions: </strong>BETA-TAVI tests a frequent but poorly studied medication decision using a randomized strategy comparison. The trial will determine whether chronic beta-blocker therapy can be continued through TAVI without a clinically unacceptable increase in early permanent pacing and will characterize the arrhythmic and hemodynamic consequences of both strategies.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT05721170.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of platelet function testing to guide antithrombotic regimens post-percutaneous coronary intervention in patients requiring therapeutic anticoagulation. 应用血小板功能测试指导需要治疗性抗凝治疗的患者经皮冠状动脉介入治疗后的抗血栓方案。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-10-27 DOI: 10.1016/j.carrev.2026.10.013
Daniel J Snyder, Mahesh V Madhavan, Seokyu Shin, Noah Chen, Megha Prasad, Michael B Collins, Margaret McEntegart, Ajay J Kirtane, Jeffrey W Moses
{"title":"The use of platelet function testing to guide antithrombotic regimens post-percutaneous coronary intervention in patients requiring therapeutic anticoagulation.","authors":"Daniel J Snyder, Mahesh V Madhavan, Seokyu Shin, Noah Chen, Megha Prasad, Michael B Collins, Margaret McEntegart, Ajay J Kirtane, Jeffrey W Moses","doi":"10.1016/j.carrev.2026.10.013","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.013","url":null,"abstract":"<p><strong>Background: </strong>Platelet reactivity testing may help tailor antithrombotic regimens after percutaneous coronary intervention (PCI). We sought to describe antithrombotic practices and assess 30-day outcomes in patients treated at an academic cardiac catheterization laboratory who underwent platelet reactivity testing following PCI while concurrently on oral anticoagulation (AC).</p><p><strong>Methods: </strong>Patients on oral AC who underwent PCI and received platelet reactivity testing at an academic medical center between 1/2012 and 9/2022 were reviewed. Patients were grouped by high on-treatment platelet reactivity (PRU ≥208) and a low on-treatment platelet reactivity (PRU <208) status and then analyzed based on whether they were continued on dual antiplatelet therapy (DAPT) or de-escalated to single antiplatelet therapy (SAPT). Rates of major bleeding and stent thrombosis up to 30 days post-PCI were compared using univariate and multivariate analyses.</p><p><strong>Results: </strong>156 patients were included (mean age 74, 72% male). Post-PCI, platelet reactivity testing revealed adequate platelet inhibition (PRU < 208) in 120 patients (77%) and inadequate inhibition (PRU≥208) in 36 patients (23%). In the group with adequate inhibition, 78 patients (65%) were de-escalated to SAPT. Compared to individuals with adequate inhibition that were continued on DAPT, patients in the SAPT group had a lower rate of major bleeding 30 days post-PCI (1.3% vs. 9.5%, p = 0.05) and with no increase in stent thrombosis rates. In the group with inadequate inhibition, 53% of patients were de-escalated to SAPT, most often with an alternative P2Y12 inhibitor. Compared to individuals with inadequate inhibition that were continued on DAPT, these patients had lower rates of major bleeding at 30 days (0% vs. 12%, p = 0.23) and similar rates of stent thrombosis.</p><p><strong>Discussion: </strong>In this analysis of a high bleeding and ischemic risk cohort of patients on concurrent AC undergoing PCI at a high-volume academic medical center, patients managed with SAPT post-PCI experienced lower rates of bleeding without a clear increase in ischemic events compared to those continued on DAPT. Antiplatelet de-escalation was left to the treating physician's discretion, and larger prospective studies are needed to corroborate the safety and utility of this strategy in clinical practice.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter by Serter regarding the article, "One-year outcomes after hybrid DES-DCB and two-stent strategies for true distal left main bifurcation lesions: A single-center registry". Serter关于文章“混合DES-DCB和双支架策略治疗真左主干远端病变的一年结果:单中心注册”的信。
IF 2.3
Cardiovascular Revascularization Medicine Pub Date : 2026-10-23 DOI: 10.1016/j.carrev.2026.10.014
Berkay Serter, Kaan Gökçe, Ahmet Güner
{"title":"Letter by Serter regarding the article, \"One-year outcomes after hybrid DES-DCB and two-stent strategies for true distal left main bifurcation lesions: A single-center registry\".","authors":"Berkay Serter, Kaan Gökçe, Ahmet Güner","doi":"10.1016/j.carrev.2026.10.014","DOIUrl":"https://doi.org/10.1016/j.carrev.2026.10.014","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书